File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamole

TitleReduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamole
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date1995
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/
Citation
Arthritis And Rheumatism, 1995, v. 38 n. 2, p. 248-253 How to Cite?
AbstractObjective. To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD. Methods. An improved filtration technique was used to measure RCD in 15 patients with RA, 18 patients with RV, and 20 age- and sex-matched normal control subjects. Washed erythrocytes suspended in buffer, at 5% hematocrit, were filtered through 4.7μ Nuclepore Hemafil PC membranes. The initial steady-state relative filtration pressure (iRFP) was used as an index to assess RCD. A lower iRFP value reflects increased deformability, a higher value reflects a decrease. For each sample, 2 cell suspensions were prepared, one blank (control) and one containing 5 μM dipyridamole. Results. The mean iRFP values of cells obtained from patients with RV were significantly higher than those of cells obtained from normal controls. There were no appreciable differences in iRFP between RA patients and normal controls. When the erythrocytes were pretreated in vitro with 5 μM dipyridamole before filtration, their deformability improved markedly (iRFP values were reduced) in all study subjects, compared with untreated cells. Conclusion. RCD is reduced in patients with RV, and treatment with dipyridamole may be beneficial if reduced RCD contributes to impaired microvascular perfusion.
Persistent Identifierhttp://hdl.handle.net/10722/91675
ISSN
2015 Impact Factor: 8.955
2015 SCImago Journal Rankings: 3.206
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, CSen_HK
dc.contributor.authorSaniabadi, ARen_HK
dc.contributor.authorBelch, JJFen_HK
dc.date.accessioned2010-09-17T10:23:10Z-
dc.date.available2010-09-17T10:23:10Z-
dc.date.issued1995en_HK
dc.identifier.citationArthritis And Rheumatism, 1995, v. 38 n. 2, p. 248-253en_HK
dc.identifier.issn0004-3591en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91675-
dc.description.abstractObjective. To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD. Methods. An improved filtration technique was used to measure RCD in 15 patients with RA, 18 patients with RV, and 20 age- and sex-matched normal control subjects. Washed erythrocytes suspended in buffer, at 5% hematocrit, were filtered through 4.7μ Nuclepore Hemafil PC membranes. The initial steady-state relative filtration pressure (iRFP) was used as an index to assess RCD. A lower iRFP value reflects increased deformability, a higher value reflects a decrease. For each sample, 2 cell suspensions were prepared, one blank (control) and one containing 5 μM dipyridamole. Results. The mean iRFP values of cells obtained from patients with RV were significantly higher than those of cells obtained from normal controls. There were no appreciable differences in iRFP between RA patients and normal controls. When the erythrocytes were pretreated in vitro with 5 μM dipyridamole before filtration, their deformability improved markedly (iRFP values were reduced) in all study subjects, compared with untreated cells. Conclusion. RCD is reduced in patients with RV, and treatment with dipyridamole may be beneficial if reduced RCD contributes to impaired microvascular perfusion.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/en_HK
dc.relation.ispartofArthritis and Rheumatismen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshArthritis, Rheumatoid - complicationsen_HK
dc.subject.meshDipyridamole - therapeutic useen_HK
dc.subject.meshErythrocyte Deformability - drug effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFiltration - methodsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLeukocyte Counten_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlatelet Counten_HK
dc.subject.meshPressureen_HK
dc.subject.meshVasculitis - blood - etiologyen_HK
dc.titleReduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamoleen_HK
dc.typeArticleen_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/art.1780380214en_HK
dc.identifier.pmid7848316-
dc.identifier.scopuseid_2-s2.0-0028817092en_HK
dc.identifier.volume38en_HK
dc.identifier.issue2en_HK
dc.identifier.spage248en_HK
dc.identifier.epage253en_HK
dc.identifier.isiWOS:A1995QF43300013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridSaniabadi, AR=18936909200en_HK
dc.identifier.scopusauthoridBelch, JJF=7101752870en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats